for RPT-04402, a first-in-class molecular glue of specific protein phosphatase 2A (PP2A) complexes. Springworks will be responsible for global development and commercialization of RPT-04402, now named ...

PP2A is a critical enzyme in regulating protein de-phosphorylation and its reactivation is fundamental for tumour suppression, but it has been historically hard to target. PP2A mutations ... oncogenic ...

making cancer cells more vulnerable to immune attacks, particularly in cases resistant to conventional anti-PD-1 therapy. Efforts to target the CD2-CD58 axis are ongoing in clinical trials.

but it has been historically hard to target. PP2A mutations are oncogenic drivers in molecularly defined subsets of uterine cancer and represent a targetable subset of patients with a high unmet ...